Stock Update On Ivan, Prot, And Arql From Pennytobuck; Arqule, Ivanhoe, Proteonomix-vy canis majoris

PROTEONOMIX, INC. (OTCBB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the PROT investment opportunity to institutional investors. The trip is scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). Mr. Cohen will also discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model. In their release from August 17th, 2010, their recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC., a Nevis Island limited liability company. PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. To receive additional information about PROT, please visit the website at .www.proteonomix.com/ ArQule, Inc. (NASDAQ:ARQL) recently reported it’s financial results for the second quarter of 2010. For the quarter ended June 30, 2010, ARQL reported a net loss of $8,227,000 or $0.18 per share, compared with a net loss of $8,272,000 or $0.19 per share, for the second quarter of 2009. For the six-month period ended June 30, 2010, the Company reported a net loss of $17,979,000 or $0.40 per share, compared to a net loss of $18,180,000 or $0.41 per share, for the six-month period ended June 30, 2009. At June 30, 2010, ARQL had a total of approximately $111,738,000 in cash, equivalents and marketable securities, which includes $16,200,000 drawn down in 2008 under notes payable that are collateralized by ARQLs auction rate securities. Net of these notes, at June 30, 2010, ARQL had a total of $95,538,000. On July 2, 2010, ARQL retired the notes payable at June 30, 2010 under its revolving credit line agreement with UBS AG following the redemption at par value of all $22.9 million of ARQLs auction rate securities that had been brokered by UBS AG. ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. ARQLs targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ARQLs lead product, in Phase 2 and upcoming Phase 3 clinical development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase. To receive additional information about ARQL, please visit the website at .www.arqule.com Ivanhoe Energy Inc. (NASDAQ:IVAN) recently reported announced that Sunwing Energy Ltd., IVAN’s wholly-owned subsidiary, has started drilling Yixin-2, located in its Zitong gas exploration block in the Sichuan Province of China. This well follows the commencement of drilling of the Zitong-1 well in mid-June 2010. Yixin-2 is being drilled as a twin well of Yixin-1, a well drilled by Sunwing in 2007 that generated significant preliminary gas flow rates. These rates, however, could not be confirmed before the well was shut-in due to a surface equipment failure during the initial hours of the testing program. Yixin-2 will be directionally drilled to allow the second wellbore to be located within 100 metres of the Yixin-1 at total depth. Yixin-2 is targeting gas in fractured reservoir formations similar to those that have led to enormous gas developments in various tight gas projects in North America. Total depth of the Yixin-2 well is planned to be approximately 4,200 metres and it is expected to take up to six months to drill and test the well. Yixin-2 is expected to cost approximately US$8.5 million. Design of any stimulation of the well using fracing technologies will be determined following evaluation of the test results. Progress update on Zitong-1 well At the Zitong-1 well, the rig has run and cemented the 9 5/8 inch intermediate casing to a depth of 3,018 metres. Following pressure testing of the casing and blow-out preventers, drilling will continue to move ahead to a planned total depth of approximately 4,500 metres. The Zitong-1 and Yixin-2 wells are targeting structures with natural gas potential in the range of 0.3 to 0.5 trillion cubic feet. Ivanhoe Energy Inc. is an independent, international heavy oil development and production company focused on pursuing long-term growth in its reserves and production using advanced technologies, including its proprietary, patented heavy to light upgrading process (HTL(TM)). To receive additional information about IVAN, please visit the website at www.ivanhoeenergy.com. For FREE Daily Stock Alerts & Updates Signup At: .pennytobuck.com/signup THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( .pennytobuck../disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.. report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to .pletely release them from any and all liability due to any and all loss (mo.ary or otherwise), damages (mo.ary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB) 相关的主题文章: